Kodiak Sciences (KOD)

• Market cap: $510M
• 1 day: 4.32%
• 5 days: 0.52%
• 1 month: -8.7%
• 3 months: 158.02%
• 6 months: 179.71%
• Year to date: 11.95%
• 1 year: 260.07%
• 5 years: -81.86%
• 10 years: -5.02%
• Sector: Healthcare
• Industry: Biotechnology

About: Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.

Employees: 121

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

29% more capital invested

Capital invested by funds: $120M [Q1] → $156M (+$35.3M) [Q2]

3% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 33

2.47% less ownership

Funds ownership: 81.46% [Q1] → 78.99% (-2.47%) [Q2]

8% less funds holding

Funds holding: 106 [Q1] → 98 (-8) [Q2]

50% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 16

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $5
• Avg. target: $9
• High target: $15

3 analyst ratings

• positive: 0 0%
• neutral: 2 67%
• negative: 1 33%

HC Wainwright & Co. Matthew Caufield	$5	Neutral Maintained	18 Aug 2025
Barclays Gena Wang	$7	Underweight Maintained	14 Aug 2025
JP Morgan Anupam Rama	$15	Neutral Upgraded	14 Aug 2025